



AGM 2022

Julie Phillips | Managing Director

20th December 2022

An Australian biotechnology company focused on growing Australia's vaccine and pharmaceutical development and manufacturing capability



Safe Harbour Statement

This presentation is provided to you for information purposes only and should not be construed as investment advice or an offer, and shall not form part of an offer, or solicitation to buy or sell any securities or derivatives. It should not be considered as an invitation to subscribe for or purchase any securities in Opal Biosciences Limited (“Opal”), or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in Opal will be entered into on the basis of this presentation.

This presentation contains forward-looking statements which are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, at the date this presentation was prepared, are expected to take place. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Opal. Opal cannot and does not give any assurance that the results, performance or achievements expressed or implied by the forward looking statements contained in this presentation will actually occur and you should not place reliance on these forward looking statements.

To the maximum extent permitted by applicable laws, Opal and its affiliates make no representation and can give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility for the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

The contents of this presentation are confidential. The presentation is being provided to you on the condition that you do not reproduce or communicate it to, or disclose it to, or discuss it with, any other person without the prior written permission of Opal.



Board & Management

Board of Directors

Ken Windle
Chairman

Former senior international positions at GSK including Head of Global Commercialization.

Julie Phillips
Managing director

Multinational pharma background in regulatory affairs, health economics and clinical trials

Damien Hannes
Non-executive director

A well-known Australian businessman with international and local advisory roles.

Company Secretary

Melanie Leydin



FY22 Highlights



\$250,000 placement in Sep 2021;
\$162,431 raised from option exercise;
\$87,569 raised from placement post-year end



Company strategy re-focus: to establish Australian small-scale manufacturing facility for clinical trial supplies



Three grant applications lodged to support new strategy (partners Formulytica Pty Ltd; University of Western Australia)



Board change: Mr Hugh Morgan AC and Mr Peter Snowball retire from the board; Mr Damien Hannes (chairman of BioDiem Ltd) joins as a non-executive director





Population scale products portfolio



- Local market and export
- Vaccine portfolio: manufacture/fill & finish
- Inhalation products
- Essential sterile pharmaceutical products
- Other dosage forms

2025 Growth Vision
– Boronia Biotech
Precinct

*- full onshore development and
manufacture capability*



Company focus HY21: GSK site

GSK Boronia manufacturing site sale

- EOI lodged 18 Mar 2021
- New site owner announced & discussions opened (June '21) to create a life sciences precinct
- Funds returned to applicants for capital raising to acquire Formulytica Pty Ltd and share placement completed in September 2021 to explore Boronia opportunity
 - costing analysis conducted based on potential manufacturing contracts.
- Discussions undertaken with governments, industry groups, local and international companies, universities, the site owner and others to develop a business plan for the site.
- Submission of applications to
 - Approach to Market (July 2021) – none awarded but option for \$5m grant application
 - Modern Manufacturing Scheme (Translation Stream) (March 2021) – unsuccessful
 - Modern Manufacturing Scheme (Integration Stream) (January 2022) – unsuccessful
- Review of alternative sites re-commenced
 - Perth option identified





Company focus CY22: Perth site

- Perth manufacturing site
- WA visit – potential facility sites, UWA, WA government (May 2022)
- Medical Research Future Fund (MRFF): mRNA Clinical Trial Enabling Infrastructure grant
 - Professor Archa Fox (University of Western Australia) contacted
 - Western Australian (WA) government contacted
 - Grant application finalized and submitted 15 Jul 2022
- Medical Research Future Fund (MRFF): National Critical Research Infrastructure grant
 - Grant application finalized and submitted 7 Sep 2022
- Western Australian Investment Attraction Fund EOI submitted (May 2022)
 - Invited to submit final application (Aug 2022)
 - Full application finalized and submitted (Oct 2022)


Results awaited.




Project Overview

- Small scale pharmaceutical manufacturing facility
- Fee-for-service operation
 - Manufacture to meet relevant global regulatory standards
- Focus on personalised/precision medicine
- Novel mRNA lung cancer vaccine candidate development with partners UWA and Formulytica Pty Ltd


mRNA vaccine targeting lung cancer



mRNA vaccine targeting lung cancer



Vaccine development






Lead candidate production for clinical testing



New sterile facility
for advanced manufacture

- small scale topical and injectable products
- development and manufacture incl for clinical trials





Outlook for FY23

- Grant funding
- Partnership with Formulytica Pty Ltd
- Capital raise for balance of funding (as required)
- Execute plan to **establish small scale manufacturing capability for sterile liquid products including vaccines.**





AGM 2022

Julie Phillips | Managing Director

20th December 2022

An Australian biotechnology company focused on growing Australia's vaccine and pharmaceutical development and manufacturing capability